What Abiraterone Acetate Treats: Main Uses and Benefits

Abiraterone acetate is a key oral treatment used exclusively in the management of advanced prostate cancer. Its therapeutic benefit centers on achieving systemic control over the disease process and is used for managing certain distressing symptoms, and supports general well-being during symptomatic phases.

This medication is used to treat a certain type of prostate cancer that has spread to other parts of the body. The medication is relevant for easing symptoms in conditions where a certain type of prostate cancer is the source of distress. It is commonly used for both high-risk castration-sensitive prostate cancer (mCSPC) and metastatic castration-resistant prostate cancer (mCRPC), which are conditions characterized by periods of heightened symptoms.

The therapy is commonly used to help with delaying disease progression and assists with managing the symptoms that accompany advanced disease. It is often applied in scenarios where additional management of discomfort is required. Abiraterone acetate is applied in addressing symptom clusters that may become intense or disruptive, particularly severe cancer-related pain associated with spread to the bone.

Quick Fact: Relief for Pain and Systemic Burden The therapy may help with the management of pain progression and contributes to easing the overall symptom load, which assists with maintaining functional stability.

Regulatory References

1. NIH MedlinePlus Drug Information

Eligibility for Abiraterone Acetate: Official Regulatory Statements

Abiraterone acetate is indicated for use exclusively in adult men. Its official regulatory profile strictly defines populations for whom use is prohibited or requires special caution based on pre-existing conditions.

Classification	Population or Condition
Contraindicated	Women who are or may become pregnant.
Contraindicated	Patients with known hypersensitivity to the drug or its excipients.
Contraindicated	Patients with baseline severe hepatic impairment (Child-Pugh Class C).
Conditional Use	Patients with moderate hepatic impairment (Child-Pugh Class B) require dosage reduction and intensive monitoring of liver function.
Caution/Monitoring	Patients with a history of cardiovascular disease (including heart failure), uncontrolled hypertension, or uncorrected hypokalemia require careful management, as the drug was not studied in patients with certain severe heart conditions (e.g., LVEF < 50% or NYHA Class III/IV heart failure).

The safety and effectiveness of abiraterone acetate have not been established in pediatric patients or in patients with severe renal impairment.

Interactions with other medicines and products

Food Effect: Abiraterone acetate must be taken on an empty stomach because consumption with food, particularly a high-fat meal, significantly increases the amount of the drug absorbed into the bloodstream. This change in exposure can raise the risk of side effects. To maintain consistent exposure, no food should be consumed for at least two hours before the dose or for at least one hour after the dose.

Enzyme Inducers and Inhibitors: Abiraterone is a substrate for the enzyme CYP3A4 and an inhibitor of the enzymes CYP2D6 and CYP2C8. Regulatory documents state that co-administration with strong CYP3A4 inducers, such as rifampin, should be avoided as it can substantially decrease the drug's exposure. If a strong CYP3A4 inducer is medically required, a change in the dosing frequency of Abiraterone acetate is specified.

Since Abiraterone is an inhibitor of CYP2D6 and CYP2C8, it may increase the concentration of medicines metabolized by these enzymes. Co-administration with CYP2D6 substrates that have a narrow therapeutic index should be avoided; if necessary, caution is required, and a dose reduction for the interacting medicine must be considered. Furthermore, cases of hypoglycemia have been documented when Abiraterone acetate was used with certain diabetes medications like pioglitazone and repaglinide, requiring blood sugar monitoring.

Combination with Radium Ra 223 dichloride is not recommended based on a clinical trial that showed an increased incidence of fractures and deaths.

The core mechanism involves the active drug, Abiraterone, acting as a selective inhibitor of the enzyme Cytochrome P450 17A1 ( CYP17A1). This enzyme is essential for synthesizing androgens (male hormones) in the adrenal glands, testes, and local tissues. By blocking CYP17A1 activity at multiple sites, the drug initiates a systemic mechanistic cascade that leads to a profound and sustained deprivation of androgens, thereby reducing the signaling mediated by the androgen receptor.

Inhibiting CYP17A1 also blocks the body’s synthesis of cortisol. This causes precursor molecules to accumulate and be shunted into the mineralocorticoid pathway, resulting in the overproduction of mineralocorticoid precursors. The co-administered corticosteroid (e.g., prednisone) acts as a necessary mechanistic complement to counteract this physiological cascade by suppressing the ACTH feedback loop, thereby limiting the accumulation of mineralocorticoid precursors, an effect required for the primary anti-androgenic mechanism to be physiologically effective.

How Abiraterone Acetate is Used: Official Administration Guidelines

Abiraterone acetate is administered as a continuous, once-daily oral therapy. The medication is formulated as tablets in several strengths, including the conventional 250 mg and 500 mg, and a micronized 125 mg form.

---

Standard Dosing and Administration Conditions

The standard daily dose is 1,000 mg using the conventional tablets, or 500 mg using the micronized tablets. This total amount must be taken as a single unit once a day. A critical instruction for the conventional 1,000 mg dose is that it must be taken on an empty stomach: this is defined as at least one hour before a meal or at least two hours after a meal. The tablets must be swallowed whole with water and must not be crushed, chewed, or split.

---

Mandatory Co-Treatment

Abiraterone acetate must always be used in combination with a low-dose corticosteroid, typically prednisone or prednisolone. The required corticosteroid dose is usually 5 mg once or twice daily, depending on the specific medical indication. Additionally, patients are required to continue chemical or surgical castration (gonadotropin-releasing hormone analog therapy or orchiectomy) during the entire course of treatment.

---

Use Over Time and Adjustments

Treatment is generally continuous until the treating physician determines that the disease has progressed or that unacceptable toxicity has developed. For patients with pre-existing moderate hepatic impairment, the starting dose of the conventional formulation is officially reduced to 250 mg once daily. If a dose is missed, patients are instructed to take only the next scheduled dose and not to take two doses to compensate.

Abiraterone acetate: Recent Clinical Evidence

Abiraterone acetate is an androgen biosynthesis inhibitor used in combination with a corticosteroid (such as prednisone) for the treatment of advanced prostate cancer. Recent clinical trials have established its role in two main settings:

---

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Evidence from large-scale, randomized clinical trials established the use of abiraterone acetate in men with mCRPC, both before and after receiving chemotherapy (docetaxel). These studies consistently reported a statistically significant improvement in Overall Survival (OS) and radiographic Progression-Free Survival (rPFS) compared to placebo plus prednisone.

---

Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

A major development has been the expansion of abiraterone acetate's use to men with newly diagnosed metastatic castration-sensitive prostate cancer, particularly those considered high-risk. Key findings from the LATITUDE trial demonstrated that adding abiraterone acetate and prednisone to standard Androgen Deprivation Therapy (ADT) resulted in a lower risk of death and a longer time without radiographic disease progression compared to ADT alone. This finding has incorporated abiraterone acetate into the standard of care for this patient group.

---

Ongoing Research Areas

Clinical research continues to explore the optimal integration of abiraterone acetate. Active areas of study include:

• Combination Therapies: Investigating its use in combination with newer agents (e.g., PARP inhibitors) or chemotherapy in various disease stages.
• Low-Dose Regimens: Evaluating lower-dose formulations of abiraterone acetate taken with food to potentially achieve comparable drug exposure while reducing cost.
• Predictive Biomarkers: Searching for biological markers to identify patients most likely to benefit from the treatment.

Key Studies & References

1. Abiraterone in Metastatic Prostate Cancer before Chemotherapy: COU-AA-302 Trial

Common questions about Abiraterone acetate (FAQ)

Q: What is Abiraterone acetate used for?

Abiraterone acetate is an anti-cancer medicine. According to official product information, it is used to treat metastatic castration-resistant prostate cancer (mCRPC), which means the prostate cancer has spread and is no longer responding to treatments that lower testosterone (surgical or medical castration).

---

Q: How does Abiraterone acetate work in the body?

Studies and official information indicate that Abiraterone acetate works by inhibiting an enzyme called CYP17. This enzyme is crucial for the production of androgens, which are male hormones. By reducing androgen levels, the medicine helps slow the growth of prostate cancer cells.

---

Q: Is Abiraterone acetate a type of chemotherapy?

No, Abiraterone acetate is not a traditional chemotherapy medicine. Instead, it is classified as an androgen biosynthesis inhibitor, which works by reducing the production of androgens (male hormones) that can fuel prostate cancer growth.

---

Q: Is Abiraterone acetate used for other types of cancer besides prostate cancer?

According to the official product information, Abiraterone acetate is approved specifically for the treatment of prostate cancer. It is indicated for patients with metastatic castration-resistant prostate cancer (mCRPC), and is typically used in combination with prednisone or prednisolone.

---

Q: Does taking Abiraterone acetate mean I will stop taking other hormone-lowering treatments?

Official product information indicates that Abiraterone acetate is intended to be used continuously alongside treatments that maintain low testosterone levels. This includes ongoing GnRH analog therapy or continuing after a surgical orchiectomy (surgical castration).

---

Q: Can Abiraterone acetate cause problems with my liver?

Studies and official information indicate that liver problems (hepatotoxicity) have been reported, including serious liver failure in rare cases. Due to this risk, the official product label specifies that liver function tests (LFTs) must be performed before starting and throughout treatment to monitor liver health.

---

Q: Do women take Abiraterone acetate?

Official regulatory documents specify that Abiraterone acetate is not indicated for use in women. Due to its potential to affect hormones and its risk of harm to a developing fetus, the product label contains strong warnings regarding use in women who are pregnant or may become pregnant.

---

Q: Why is prednisone or prednisolone often prescribed with Abiraterone acetate?

Abiraterone acetate can cause an increase in mineralocorticoid levels in the body, which may lead to side effects such as high blood pressure and low potassium. To help manage and reduce these effects, the official guidance requires that Abiraterone acetate be used in combination with prednisone or prednisolone.

How to Store and Dispose of Abiraterone Acetate

Abiraterone acetate tablets must be stored according to specific regulatory requirements to maintain drug stability and protection.

Storage Condition	Requirement
Temperature	Store at 20 C to 25 C (68 F to 77 F), with permitted excursions between 15 C and 30 C (59 F and 86 F).
Protection	Keep the bottle closed tightly to protect the tablets from moisture. Store in the original container.
Access	Store out of the reach of children and pets.

For disposal of unused or expired medication, it is instructed not to flush Abiraterone acetate down the toilet. Dispose of the medicine through a drug take-back program or by following the United States FDA's recommended toss-away guidelines for medicines without specific instructions.